BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 21261712)

  • 1. Is endoscopic surveillance for non-dysplastic Barrett's esophagus cost-effective? Review of economic evaluations.
    Hirst NG; Gordon LG; Whiteman DC; Watson DI; Barendregt JJ
    J Gastroenterol Hepatol; 2011 Feb; 26(2):247-54. PubMed ID: 21261712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surveillance of Barrett's oesophagus: exploring the uncertainty through systematic review, expert workshop and economic modelling.
    Garside R; Pitt M; Somerville M; Stein K; Price A; Gilbert N
    Health Technol Assess; 2006 Mar; 10(8):1-142, iii-iv. PubMed ID: 16545207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness model of endoscopic screening and surveillance in patients with gastroesophageal reflux disease.
    Gerson LB; Groeneveld PW; Triadafilopoulos G
    Clin Gastroenterol Hepatol; 2004 Oct; 2(10):868-79. PubMed ID: 15476150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of endoscopic surveillance of non-dysplastic Barrett's esophagus.
    Gordon LG; Mayne GC; Hirst NG; Bright T; Whiteman DC; ; Watson DI
    Gastrointest Endosc; 2014 Feb; 79(2):242-56.e6. PubMed ID: 24079411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health benefits and cost effectiveness of endoscopic and nonendoscopic cytosponge screening for Barrett's esophagus.
    Benaglia T; Sharples LD; Fitzgerald RC; Lyratzopoulos G
    Gastroenterology; 2013 Jan; 144(1):62-73.e6. PubMed ID: 23041329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improving cost-effectiveness of endoscopic surveillance for Barrett's esophagus by reducing low-value care: a review of economic evaluations.
    Vissapragada R; Bulamu NB; Brumfitt C; Karnon J; Yazbeck R; Watson DI
    Surg Endosc; 2021 Nov; 35(11):5905-5917. PubMed ID: 34312726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endoscopic surveillance of Barrett's esophagus: a cost-effectiveness comparison with mammographic surveillance for breast cancer.
    Streitz JM; Ellis FH; Tilden RL; Erickson RV
    Am J Gastroenterol; 1998 Jun; 93(6):911-5. PubMed ID: 9647017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An economic analysis of endoscopic ablative therapy for management of nondysplastic Barrett's esophagus.
    Das A; Wells C; Kim HJ; Fleischer DE; Crowell MD; Sharma VK
    Endoscopy; 2009 May; 41(5):400-8. PubMed ID: 19418393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of endoscopic screening followed by surveillance for Barrett's esophagus: a review.
    Barbiere JM; Lyratzopoulos G
    Gastroenterology; 2009 Dec; 137(6):1869-76. PubMed ID: 19840798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Screening and Surveillance for Barrett's Esophagus: Is It Cost-Effective?
    Inadomi JM; Saxena N
    Dig Dis Sci; 2018 Aug; 63(8):2094-2104. PubMed ID: 29948571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Barrett's esophagus: a new look at surveillance based on emerging estimates of cancer risk.
    Provenzale D; Schmitt C; Wong JB
    Am J Gastroenterol; 1999 Aug; 94(8):2043-53. PubMed ID: 10445526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What is the best management strategy for high grade dysplasia in Barrett's oesophagus? A cost effectiveness analysis.
    Shaheen NJ; Inadomi JM; Overholt BF; Sharma P
    Gut; 2004 Dec; 53(12):1736-44. PubMed ID: 15542506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnosis and Surveillance of Barrett's Esophagus: Addressing the Transatlantic Divide.
    Ghaus S; Neumann H; Muhammad H; Tontini GE; Ishaq S
    Dig Dis Sci; 2016 Aug; 61(8):2185-2193. PubMed ID: 27038446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective multivariate analysis of clinical, endoscopic, and histological factors predictive of the development of Barrett's multifocal high-grade dysplasia or adenocarcinoma.
    Weston AP; Badr AS; Hassanein RS
    Am J Gastroenterol; 1999 Dec; 94(12):3413-9. PubMed ID: 10606296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Screening and surveillance for Barrett esophagus in high-risk groups: a cost-utility analysis.
    Inadomi JM; Sampliner R; Lagergren J; Lieberman D; Fendrick AM; Vakil N
    Ann Intern Med; 2003 Feb; 138(3):176-86. PubMed ID: 12558356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic value of narrow-band imaging versus white light endoscopy for the diagnosis and surveillance of Barrett's esophagus: Cost-consequence model.
    Furneri G; Klausnitzer R; Haycock L; Ihara Z
    PLoS One; 2019; 14(3):e0212916. PubMed ID: 30865673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How to get the most out of costly Barrett's oesophagus surveillance.
    Braden B; Jones-Morris E
    Dig Liver Dis; 2018 Sep; 50(9):871-877. PubMed ID: 29730158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Surveillance in patients with long-segment Barrett's oesophagus: a cost-effectiveness analysis.
    Kastelein F; van Olphen S; Steyerberg EW; Sikkema M; Spaander MC; Looman CW; Kuipers EJ; Siersema PD; Bruno MJ; de Bekker-Grob EW;
    Gut; 2015 Jun; 64(6):864-71. PubMed ID: 25037191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Barrett's oesophagus: Current controversies.
    Amadi C; Gatenby P
    World J Gastroenterol; 2017 Jul; 23(28):5051-5067. PubMed ID: 28811703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are screening and surveillance for Barrett's oesophagus really worthwhile?
    Sharma P; Sidorenko EI
    Gut; 2005 Mar; 54 Suppl 1(Suppl 1):i27-32. PubMed ID: 15711005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.